SEC Form 4 · accession 0001209191-16-089857
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael D. Clayman
Officer — President and CEO · Director
Period of report
Jan 4, 2016
Accepted (ET)
Jan 6, 2016 · 4:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $18.20 | Jan 4, 2016 | A | 155,000 | A | — | Jan 3, 2026 | Common Stock | 155,000 | 155,000 | D |
| Restricted Stock Unit AwardF2,F3 | $0.00 | Jan 4, 2016 | A | 66,600 | A | — | Jul 1, 2018 | Common Stock | 66,600 | 66,600 | D |
Explanation of responses
- F1Twenty-five percent (25%) of the shares subject to the option shall vest one year after January 04, 2016; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following the one year anniversary of January 04, 2016, so that all of the shares subject to the option shall be vested four (4) years after January 04, 2016.
- F2Represents the maximum number of shares deliverable under the restricted stock unit award.
- F3The amount and vesting of the shares under the restricted stock unit award is based on the satisfaction of certain performance conditions that were established at the time of the Compensation Committee's approval of the restricted stock unit award on December 17, 2015. One-third (1/3) of the shares under the restricted stock unit award will vest on each of the date the Board or Compensation Committee certifies the achievement of the performance conditions and the first and second anniversaries of such date.